Monte Rosa Therapeutics shares surge on strong Q4 revenue beat

Published 20/03/2025, 16:04
Monte Rosa Therapeutics shares surge on strong Q4 revenue beat

BOSTON - Monte Rosa Therapeutics , Inc. (NASDAQ:GLUE) reported fourth quarter revenue that significantly exceeded analyst expectations, sending shares up 6.9% in early trading.

The clinical-stage biotechnology company, which develops novel molecular glue degrader-based medicines, announced Q4 revenue of $60.64 million, surpassing the consensus estimate of $51.19 million. This marks the company’s first quarter of substantial revenue generation, derived from collaboration agreements with Roche and Novartis (SIX:NOVN).

Monte Rosa reported a net income of $13.4 million for Q4, compared to a net loss of $33.3 million in the same quarter last year. The company’s strong financial position was bolstered by a $150 million upfront payment from its recent licensing agreement with Novartis for VAV1 molecular glue degraders, including MRT-6160.

"We continue to make excellent progress with our clinical and preclinical molecular glue degrader programs, targeting areas poorly addressed by conventional pharmaceutical approaches and with expansive therapeutic potential," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

The company provided updates on its clinical programs, including encouraging early signals from its MRT-2359 study in castration-resistant prostate cancer patients. Monte Rosa plans to focus development efforts on this indication moving forward.

Additionally, the company reported positive results from its Phase 1 study of MRT-6160, demonstrating deep VAV1 degradation and a favorable safety profile. These data support advancement into Phase 2 studies for potential applications in immune-mediated diseases.

Monte Rosa ended the quarter with $377 million in cash and equivalents, which it expects will fund operations into 2028.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.